4.5 Article

Chemogenetics-A Transformational and Translational Platform

Journal

JAMA NEUROLOGY
Volume 72, Issue 11, Pages 1361-1366

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2015.1921

Keywords

-

Funding

  1. National Institutes of Health [1U01MH105892-01]

Ask authors/readers for more resources

Neurologic disorders are frequently a result of inappropriate electrical and/or chemical signaling of neurons and glia. Ultimate remediation would necessitate reprogramming these signals. Historically, correcting neuronal and glial signaling is accomplished via drug therapy/administration, although they frequently fail to effectively and fully treat the underlying disorder. Developments in basic research have produced several new classes of potential therapeutics to directly and precisely control neuron activity at the single-cell level. We review one such technology, Designer Receptors Exclusively Activated by Designer Drugs, and suggest its potential as a powerful tool for augmenting neuronal and glial signaling and activity for basic and translational applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available